Cytokinetics Announces Pricing for Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a price to the public of 51. 00 $ per share, before subscription of discounts and commissions. The gross proceeds from the offering for Cytokinetics, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $500 million. The offering is expected to close on May 28, 2024, subject to customary closing conditions. In addition, Cytokinetic has granted the underwriters a 30-day option to purchase up to 1,470,588 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All common shares in the offering will be sold by Cytokinetics.

JP Morgan, Goldman Sachs & Co. LLC and Morgan Stanley are acting as sole joint book-running managers for the offering.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on November 18, 2022 with the Securities and Exchange Commission (SEC), which has automatically become effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed, and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be inspected free of charge on the SEC’s website at http://www. .sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: JP Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email to prospectus-eq_fi. @jpmchase.com and [email protected]; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by e-mail at [email protected] .gs.com; or Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2^sd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. prior to registration or qualification under the securities laws of any such state or jurisdiction.

About cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class muscle activators and next-generation muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. compromised and/or declining.

Forward-looking statements

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to Cytokinetics’ expectations regarding the consummation of the offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that could cause such a difference include, but are not limited to, risks and uncertainties relating to market and other conditions and the satisfaction of customary closing conditions associated with the public offering. There can be no assurance that Cytokinetics will be able to complete the public offering on the anticipated terms, if at all. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Additional risks and uncertainties relating to the public offering, Cytokinetics and its businesses can be found under the heading “Risk Factors” in Cytokinetics’ Quarterly Report on Form 10-Q for the first quarter of 2024, which has been filed on May 10, 2024, and other documents filed with the SEC, as well as in the preliminary prospectus supplement relating to the public offering, filed with the SEC on May 22, 2024. Except as otherwise required by law, Cytokinetics does not undertakes no obligation to update any forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which such statements are based.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757